ReviewLife (Basel, Switzerland)2021
Clinical Implications of Uric Acid in Heart Failure: A Comprehensive Review.
Review in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- The Role of Oxidative Stress and Inflammatory Parameters in Heart Failure.Medicina (Kaunas, Lithuania) · 2024Pooled it
- The association between uric acid and incident cardiovascular events amongst healthy, community-dwelling older adults.GeroScience · 2026Article
- Hyperuricemia Reflects Cardiometabolic Burden Rather than Left Ventricular Systolic Dysfunction Across Heart Failure Phenotypes: Insights from a Real-World Acute Heart Failure Cohort.Journal of clinical medicine · 2026Article
- Renal Biomarkers and Albuminuria Predict Early Adverse Outcomes in Cardiorenal Syndrome Type 2.Medical sciences (Basel, Switzerland) · 2026Observational
- Heart failure risk prediction based on machine learning and interpretability analysis.Frontiers in medicine · 2026Article
- Hyperuricemia in hospitalized patients with heart failure: prevalence and clinical correlates.Frontiers in medicine · 2026Article
- Circulating Biomarkers in Failing Fontan Circulation: Current Evidence and Future Directions.Journal of cardiovascular development and disease · 2025Review
- Copeptin, Routine Laboratory Parameters, and Ischemic Etiology of Heart Failure Predict Outcomes in Elderly Patients with Decompensated Heart Failure.Biomedicines · 2025Article
- Cardiometabolic Risk in Psoriatic Arthritis: A Hidden Burden of Inflammation and Metabolic Dysregulation.Metabolites · 2025Review
- Blood Biomarkers as a Non-Invasive Method for the Assessment of the State of the Fontan Circulation.Journal of clinical medicine · 2025Review
- Article
- Self-Management Task Performance and Its Association with Biomarkers in Elderly Patients with Chronic Heart Failure: A Cross-Sectional Analysis.Patient preference and adherence · 2025Article
- Machine learning prediction and SHAP interpretability analysis of heart failure risk in patients with hyperuricemia.Frontiers in cardiovascular medicine · 2025Article
- Combination of sST2/LVMI Ratio and Modified MELD Scores Predicts Mortality in End-Stage Heart Failure.International journal of molecular sciences · 2024Article
- Hyperuricemia Is Associated With Higher Mortality in Non-diabetic Heart Failure Patients.Cureus · 2024Article
- Hyperuricaemia elevates risk of short-term readmission and mortality in patients with heart failure.Open heart · 2024Article
- Biochemical indicators, cell apoptosis, and metabolomic analyses of the low-temperature stress response and cold tolerance mechanisms in Litopenaeus vannamei.Scientific reports · 2024Article
- Gender differences in the relationship between serum uric acid and the long-term prognosis in heart failure: a nationwide study.Cardiovascular diabetology · 2024Article
- Plasma catestatin levels are related to metabolic parameters in patients with essential hypertension and type 2 diabetes mellitus.Heart and vessels · 2024Article
- Celebrating Versatility: Febuxostat's Multifaceted Therapeutic Application.Life (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Affecting more than 26 million people worldwide and with rising prevalence, heart failure (HF) represents a major global health problem. Hence, further research is needed in order to abate poor HF outcomes and mitigate significant expenses that burden health care systems. Based on available data, experts agree that there is an urgent need for a cost-effective prognostic biomarker in HF. Although a significant number of biomarkers have already been investigated in this setting, the clinical utility of adding biomarker evaluation to routine HF care still remains ambiguous. Specifically, in this review we focused on uric acid (UA), a purine metabolism detriment whose role as cardiovascular risk factor has been exhaustingly debated for decades. Multiple large population studies indicate that UA is an independent predictor of mortality in acute and chronic HF, making it a significant prognostic factor in both settings. High serum levels have been also associated with an increased incidence of HF, thus expanding the clinical utility of UA. Importantly, emerging data suggests that UA is also implicated in the pathogenesis of HF, which sheds light on UA as a feasible therapeutic target. Although to date clinical studies have not been able to prove the benefits of xanthine oxidase in HF patients, we discuss the putative role of UA and xanthine oxidase in the pathophysiology of HF as a therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.